

Course Detail

MMWR Weekly – December 4, 2015

Course Number: WB2526-12012015

CE Origination Date: December 4, 2015

CE Expiration Date: January 18, 2016

Content Experts/Prepares

Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults — United States, 2005–2012

Carla Mercado, PhD, Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Ariadne K. DeSimone, Emory University School of Medicine, Atlanta, Georgia; Rollins School of Public Health, Emory University, Atlanta, Georgia.

Erika Odom, PhD, Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Kathleen Gillespie, MS, Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Carma Ayala, PhD, Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Fleetwood Loustalot, PhD, Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

CDC Grand Rounds: Prevention and Control of Skin Cancer

Meg Watson, Division of Cancer Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Cheryll Thomas, Division of Cancer Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Greta Massetti, Division of Cancer Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC

Sharon McKenna, Arizona SunWise Skin Cancer Prevention Program, Arizona Department of Health Services

Jeffrey E. Gershenwald, The University of Texas MD Anderson Cancer Center, Houston, Texas

Susan Laird, Office of the Associate Director for Science, CDC

John Iskande, Office of the Associate Director for Science, CDC

Boris Lushniak, Office of the Surgeon General, U.S. Department of Health and Human Services.

Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: N/A